Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Market Access

Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied

 April 2, 2026

KFF Medicare

Certain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied

Market AccessRead full story

Post navigation

ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH →
← Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com